In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (ATNM), with a price target of $3. The company’s shares opened today at $0.29, close to its 52-week low of $0.26.
McCarthy noted:
“Oncology (ASCO) annual meeting, Actinium presented new analysis on the first set of patients from its ongoing pivotal SIERRA trial of Iomab-B for end-stage acute myeloid leukemia (AML). Of note, the goal of the SIERRA study is to prepare and condition patients for a bone marrow transplant (BMT).”
According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -17.0% and a 24.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Currently, the analyst consensus on Actinium Pharmaceuticals is a Moderate Buy with an average price target of $4.
See today’s analyst top recommended stocks >>
The company has a one-year high of $0.87 and a one-year low of $0.26. Currently, Actinium Pharmaceuticals has an average volume of 1.51M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
